REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
13/10/2025
Voltar para busca
Dado oficial do USPTO
PLASMACAP EBA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
PLASMACAP EBA
ST13
US500000086019802Classe
1, 5, 9, 37, 40, 41, 42
Pedido
86019802
Registro
6172149
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
82
Atualização mais recente
14/10/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 9, 37, 40, 41, 42
Data de depósito
25/07/2013
Data de registro
13/10/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/10/2020
Última transação
14/10/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Mississauga, Ontario, CA
Examinador
BIBB,SCOTT
Unidade examinadora
L90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Evolve Biologics Inc.,
Therapure Biopharma Inc.
Representantes
Christopher J. Schulte MERCHANT & GOULD P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 9Classe 37Classe 40Classe 41Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Resins, namely, polysaccharide beads cross-linked to ligands for capturing proteins from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate ion exchange, mixed mode, and affinity resins
Classe 5
Biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate for human clinical use, namely, plasma protein fractions, serum albumin, immunoglobulins, coagulation factors, antihemophilic factors, clotting factors, enzymes, coenzymes, coactivators, inhibitors, and structural proteins
Classe 9
Protein chromatography equipment for capturing biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate
Classe 37
Construction of biopharmaceutical and plasma manufacturing facilities relevant to the manufacturing of biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate; consulting services in the field of construction of biopharmaceutical and plasma manufacturing services
Classe 40
Contract manufacturing services for others for biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate for research and development, and clinical use; consulting services concerning manufacturing of biologics
Classe 41
Educational services, namely, designing, arranging, and conducting training programs for research and development, manufacturing of biologics, design, construction, and use of chromatography equipment
Classe 42
Development of pharmaceutical preparations and medicines, namely, development services for others for the capture of biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate for research and development; consulting services for others concerning the capture of biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate for research and development, design of chromatography equipment, and design of biopharmaceutical and plasma manufacturing facilities, namely, scientific research and evaluation, and engineering
Publicações
Histórico de despachos e eventos da marca no USPTO.
82 publicações encontradas
CORV
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
06/07/2021
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
01/07/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
13/10/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/07/2020
PUBO
PUBLISHED FOR OPPOSITION
28/07/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/07/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/06/2020
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
17/06/2020
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
17/06/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/06/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/06/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/06/2020
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
01/01/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/12/2019
GNFR
FINAL REFUSAL E-MAILED
03/12/2019
CNFR
FINAL REFUSAL WRITTEN
03/12/2019
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
27/11/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/10/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/10/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
24/10/2019
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
23/10/2019
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
22/10/2019
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
27/09/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
27/09/2019
CNSI
SUSPENSION INQUIRY WRITTEN
27/09/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
09/09/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/02/2019
GNSL
LETTER OF SUSPENSION E-MAILED
05/02/2019
CNSL
SUSPENSION LETTER WRITTEN
05/02/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/12/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/12/2018
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/12/2018
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
08/06/2018
GNSI
INQUIRY TO SUSPENSION E-MAILED
08/06/2018
CNSI
SUSPENSION INQUIRY WRITTEN
08/06/2018
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
30/05/2018
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
24/11/2017
GNSL
LETTER OF SUSPENSION E-MAILED
24/11/2017
CNSL
SUSPENSION LETTER WRITTEN
24/11/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/10/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/10/2017
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
04/10/2017
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
20/04/2017
GNSI
INQUIRY TO SUSPENSION E-MAILED
20/04/2017
CNSI
SUSPENSION INQUIRY WRITTEN
20/04/2017
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
17/03/2017
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
13/09/2016
GNSL
LETTER OF SUSPENSION E-MAILED
13/09/2016
CNSL
SUSPENSION LETTER WRITTEN
13/09/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/08/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/08/2016
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
08/08/2016
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
09/02/2016
GNSI
INQUIRY TO SUSPENSION E-MAILED
09/02/2016
CNSI
SUSPENSION INQUIRY WRITTEN
09/02/2016
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
16/12/2015
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
30/05/2015
GNSL
LETTER OF SUSPENSION E-MAILED
30/05/2015
CNSL
SUSPENSION LETTER WRITTEN
30/05/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/04/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/04/2015
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
23/04/2015
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
25/10/2014
GNSI
INQUIRY TO SUSPENSION E-MAILED
25/10/2014
CNSI
SUSPENSION INQUIRY WRITTEN
25/10/2014
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
24/09/2014
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
24/03/2014
GNSL
LETTER OF SUSPENSION E-MAILED
24/03/2014
CNSL
SUSPENSION LETTER WRITTEN
24/03/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/02/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/02/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/02/2014
ALIE
ASSIGNED TO LIE
11/02/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/02/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/11/2013
GNRT
NON-FINAL ACTION E-MAILED
14/11/2013
CNRT
NON-FINAL ACTION WRITTEN
14/11/2013
DOCK
ASSIGNED TO EXAMINER
07/11/2013
MPMK
NOTICE OF PSEUDO MARK E-MAILED
31/07/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/07/2013
NWAP
NEW APPLICATION ENTERED
29/07/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PLASMACAP EBA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.